Abhishek S. Rao

Abhishek S. Rao

Auto-generated profile, based on publicly available information

Abhishek S. Rao

Department of Microbiology and Immunology, Drexel University College of Medicine , Philadelphia, PA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSSunil Singhal
Sunil Singhal
ARAbhishek S. Rao
Abhishek S. Rao
JSJason Stadanlick
Jason Stadanlick
KBKyle Bruns
Kyle Bruns
NSNeil T. Sullivan
Neil T. Sullivan
EEEvgeniy B. Eruslanov
Evgeniy B. Eruslanov
The clinical benefits of tumor-targeting antibodies (tAb) are modest in solid human tumors. The efficacy of many tAbs is dependent on Fc receptor (FcR)–expressing leukocytes that bind Fc fragments of tAb. Tumor-associated macrophages (TAM) and neutrophils (TAN) represent the majority of FcR+ effectors in solid tumors. A better understanding of the mechanisms by which TAMs and TANs regulate tAb response could help improve the efficacy of cancer treatments. Here, we found that myeloid effectors interacting with tAb-opsonized lung cancer cells used antibody-dependent trogocytosis (ADT) but not antibody-dependent phagocytosis. During this process, myeloid cells “nibbled off” tumor cell fragments containing tAb/targeted antigen (tAg) complexes. ADT was only tumoricidal when the tumor cells expressed high levels of tAg and the effectors were present at high effector-to-tumor ratios. If either of these conditions were not met, which is typical for solid tumors, ADT was sublethal. Sublethal ADT, mainly mediated by CD32hiCD64hi TAM, led to two outcomes: (i) removal of surface tAg/tAb complexes from the tumor that facilitated tumor cell escape from the tumoricidal effects of tAb; and (ii) acquisition of bystander tAgs by TAM with subsequent cross-presentation and stimulation of tumor-specific T-cell responses. CD89hiCD32loCD64lo peripheral blood neutrophils (PBN) and TAN stimulated tumor cell growth in the presence of the IgG1 anti-EGFR Ab cetuximab; however, IgA anti-EGFR Abs triggered the tumoricidal activity of PBN and negated the stimulatory effect of TAN. Overall, this study provides insights into the mechanisms by which myeloid effectors mediate tumor cell killing or resistance during tAb therapy. Significance: The elucidation of the conditions and mechanisms by which human FcR+ myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating solid tumors.

18 March 2025 in The Journal of Immunology
Verified
Journal Article
Closed access
ARAbhishek S Rao
Abhishek S Rao
NUNneka Ugwu
Nneka Ugwu
AOAbigail P Onufer
Abigail P Onufer
OKOgan Kartal Kumova
Ogan Kartal Kumova
ACAlison Carey
Alison Carey
Respiratory viral infections are a major contributor to mortality in children under 5 years of age, and disproportionately affect preterm neonates. Previously, using our established 3-day-old neonatal murine model of influenza virus infection, we demonstrated that treatment of neonatal mice with intranasal Lactobacillus rhamnosus GG (LGG) prior to influenza viral infection improved survival. Transcriptional analysis revealed expression of the mouse cathelicidin-related antimicrobial peptide (CRAMP, encoded by CRAMP) was downregulated in LGG-treated neonates. Mouse CRAMP is a key effector protein secreted by infected epithelial cells and resident and infiltrating immune cells, but the role of CRAMP in neonatal defense to respiratory viruses is unknown. Neonatal mice with a deleted CRAMP gene (CRAMP–/–) were intranasally infected with influenza virus. CRAMP–/– neonates had improved survival over C57BL/6 neonates after influenza viral infection (75% vs. 14%, p < 0.05). Next, immune cell recruitment to the lung of infected neonates was determined. Surprisingly, at 3-days postinfection, there was increased recruitment of neutrophils, inflammatory monocytes, and alveolar macrophages, coupled with increased proinflammatory cytokine and chemokine production in CRAMP–/– compared to C57BL/6 neonates. However, this changed over the first week of infection. C57BL/6 neonatal mice increased CRAMP production significantly, in direct contrast to their adult counterparts. Inflammatory cytokine production increased that indicated CRAMP amplified the innate immune response later in the infection. Furthermore, we identified pulmonary nonimmune cells as an important source of increased CRAMP levels as the infection progressed and CRAMP production drove mortality. These insights emphasize the age-specific role of CRAMP in influenza viral pathogenesis.

1 April 2024
Verified
Other
Open access
PDF file
SSSunil Singhal
Sunil Singhal
ARAbhishek S. Rao
Abhishek S. Rao
JSJason Stadanlick
Jason Stadanlick
KBKyle Bruns
Kyle Bruns
NSNeil T. Sullivan
Neil T. Sullivan
EEEvgeniy B. Eruslanov
Evgeniy B. Eruslanov
Supplementary Figure S9. (A and B) Representative dotplots and summary results showing the ability of TAM pretreated with blocking anti-CD64 F(ab')2 and anti-CD32 F(ab')2 fragments (5ug/ml) to kill PKH67+ A431 cells at a 1:1 E:T ratio in the presence of cetuximab (1ug/ml) in a 12 hrs FACS-based assay. Dead A431 tumor cells were defined as TO-PRO-3+PKH67+ cells. (C and D) Representative dotplots and summary results demonstrating the ability of HLA-A2neg TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after their preincubation with cetuximab-opsonized A549/HLA-A2+NY-ESO tumor cells at the indicated time points. Kruskal-Wallis multiple comparisons test. Data represented as mean ± SEM. (E) The expression of NY-ESO-1 protein in different batches of transduced A549 tumor cells. The expression of intracellular NY-ESO was evaluated by flow cytometry using NY-ESO-1 mAb (clone D1Q2U) that recognizes endogenous levels of total NY-ESO-1 protein. Non transduced A549 cells were used as a control. (F-H) Representative dotplots and cumulative data showing the ability of HLA-A2+TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after preincubation with A549/HLA-A2+NY-ESOhi (F) and A549/HLA-A2+NY-ESOlo tumor cells (G) in the presence or absence of cetuximab for 4 hrs. Wilcoxon matched pairs test for groups with (+) or without (-) Ab. * p<0,01. Kruskal-Wallis test for TAM groups co-cultured with A549/HLA-A2+NY-ESOhi or A549/HLA-A2+NY-ESOlo. Data represented as mean ± SEM. FcR+ effectors were freshly isolated for all experiments.

1 April 2024
Verified
Other
Open access
PDF file
SSSunil Singhal
Sunil Singhal
ARAbhishek S. Rao
Abhishek S. Rao
JSJason Stadanlick
Jason Stadanlick
KBKyle Bruns
Kyle Bruns
NSNeil T. Sullivan
Neil T. Sullivan
EEEvgeniy B. Eruslanov
Evgeniy B. Eruslanov
Supplementary Figure S7. (A) Cumulative flow cytometry results showing the ability of blood and tumor FcR+ effectors to kill PKH-67+A431 tumor cells in the presence of nonspecific human IgG1 or IgA2 isotype control Abs (1ug/ml) at a 2:1 E:T ratio in a 12 hrs FACS-based assay. (B and C) Cumulative results showing the kinetics of GFP+A431 tumor cell growth when co-cultured with blood and tumor FcR+ effectors for 48 hrs at a 2:1 E:T ratio in the presence of IgG1 or IgA2 isotype control Abs (1ug/ml) in the IncuCyte® Live Cell Analysis System. (D) Cumulative flow cytometry results showing the ability of blood and tumor FcR+ effectors to kill PKH-67+A549 tumor cells in the presence of nonspecific human IgG1 or IgA2 isotype control Abs (1ug/ml) at a 50:1 E:T ratio in a 12 hrs FACS-based assay. (E and F) Cumulative results showing the kinetics of GFP+A549 tumor cell growth when co-cultured with blood and tumor FcR+ effectors for 48 hrs at a 50:1 E:T ratio in the presence of IgG1 or IgA2 isotype control Abs (1ug/ml) in the IncuCyte® Live Cell Analysis System. All comparisons used one-way ANOVA with Dunnett’s multiple comparisons test. All Data are represented as mean ± SEM. Indicated FcR+ effectors were freshly isolated for all experiments.

1 April 2024
Verified
Other
Open access
SSSunil Singhal
Sunil Singhal
ARAbhishek S. Rao
Abhishek S. Rao
JSJason Stadanlick
Jason Stadanlick
KBKyle Bruns
Kyle Bruns
NSNeil T. Sullivan
Neil T. Sullivan
EEEvgeniy B. Eruslanov
Evgeniy B. Eruslanov
The clinical benefits of tumor-targeting antibodies (tAb) are modest in solid human tumors. The efficacy of many tAbs is dependent on Fc receptor (FcR)–expressing leukocytes that bind Fc fragments of tAb. Tumor-associated macrophages (TAM) and neutrophils (TAN) represent the majority of FcR+ effectors in solid tumors. A better understanding of the mechanisms by which TAMs and TANs regulate tAb response could help improve the efficacy of cancer treatments. Here, we found that myeloid effectors interacting with tAb-opsonized lung cancer cells used antibody-dependent trogocytosis (ADT) but not antibody-dependent phagocytosis. During this process, myeloid cells “nibbled off” tumor cell fragments containing tAb/targeted antigen (tAg) complexes. ADT was only tumoricidal when the tumor cells expressed high levels of tAg and the effectors were present at high effector-to-tumor ratios. If either of these conditions were not met, which is typical for solid tumors, ADT was sublethal. Sublethal ADT, mainly mediated by CD32hiCD64hi TAM, led to two outcomes: (i) removal of surface tAg/tAb complexes from the tumor that facilitated tumor cell escape from the tumoricidal effects of tAb; and (ii) acquisition of bystander tAgs by TAM with subsequent cross-presentation and stimulation of tumor-specific T-cell responses. CD89hiCD32loCD64lo peripheral blood neutrophils (PBN) and TAN stimulated tumor cell growth in the presence of the IgG1 anti-EGFR Ab cetuximab; however, IgA anti-EGFR Abs triggered the tumoricidal activity of PBN and negated the stimulatory effect of TAN. Overall, this study provides insights into the mechanisms by which myeloid effectors mediate tumor cell killing or resistance during tAb therapy.Significance:The elucidation of the conditions and mechanisms by which human FcR+ myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating solid tumors.

1 April 2024
Verified
Other
Open access
PDF file
SSSunil Singhal
Sunil Singhal
ARAbhishek S. Rao
Abhishek S. Rao
JSJason Stadanlick
Jason Stadanlick
KBKyle Bruns
Kyle Bruns
NSNeil T. Sullivan
Neil T. Sullivan
EEEvgeniy B. Eruslanov
Evgeniy B. Eruslanov
Supplementary Figure S6. (A and B) Representative experiment and summary results showing the effect of indicated blood and tumor FcR+ effectors on the growth of A431 tumor cell spheroids in the presence of cetuximab (1ug/ml). GFP+A431 cells were seeded at 500 cells/well in a round bottom ultra-low adhesion cell culture plate designed to form spheroids. Indicated FcR+ effectors were added at E:T ratio 50:1 into the spheroid cultures. The growth of tumor spheroids was monitored in the IncuCyte® Live Cell Analysis System for 48 hrs. Representative images of GFP+A431 tumor cell spheroids co-cultured with indicated effectors and cetuximab for 48 hrs taken from IncuCyte® Live Cell Analysis System (original magnification x10). Scale bar, 400 µm. Percentage of tumor cell growth inhibition/stimulation in the presence of anti-EGFR Abs was calculated at 48 hrs using the formula: (FI)(A431+Ab)-FI(A431+effectors+Ab)/FI(A431+Ab)x100%, FI-Integrated fluorescence intensity. Data are represented as mean ± SEM. Wilcoxon matched pairs test (n=7). (C) Representative dotplots showing the different levels of ADT mediated by indicated FcR+ effectors co-cultured with spheroids formed with PKH67-labeled A431 cells. FcR+ effectors were co-cultured at a E:T ratio 50:1 in the presence or absence of cetuximab for 12 hrs. Representative results from 1 of 3 experiments are shown. (D and E) Representative experiment and summary results showing the effect of PBN and TAN on the growth of GFP+A431 tumor cell spheroids in the presence of IgA anti-EGFR Ab (IgA) (1ug/ml). Experiments were performed as described in (A and B). Original magnification x10. Scale bar, 400 µm. Data are represented as mean ± SEM. Wilcoxon matched pairs test (n=5). (F) Representative dotplots showing the ADT mediated by PBN and TAN co-cultured with spheroids formed with PKH67-lableld A431 cells. PBN and TAN were co-cultured at a E:T ratio 50:1 in the presence or absence of IgA anti-EGFR Ab for 12 hrs. Representative results from 1 of 3 experiments are shown.